Medicare Enrolled

Dr. Steven Copenhaver, M.D.

Pediatric Hematology-Oncology · Dallas, TX
Speaking/Promotional
7777 FOREST LN STE B309, Dallas, TX 75230
9725666996
In practice since 2006 (19 years)
NPI: 1396784518 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Copenhaver from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Copenhaver? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Copenhaver

Dr. Steven Copenhaver is a pediatric hematology-oncology in Dallas, TX, with 19 years in practice.

Between the years covered by Open Payments, Dr. Copenhaver received a total of $16,801 from 33 pharmaceutical and/or device companies across 282 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pediatric hematology-oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Copenhaver is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice$ $16,801 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$16,801
Total received (2018-2024)
Avg $2,400/year across 7 years
Top 6% in TX for pediatric hematology-oncology
33
Companies
282
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$12,358 (73.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,443 (26.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$645
2023
$790
2022
$608
2021
$692
2020
$1,408
2019
$8,141
2018
$4,516

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Sobi, Inc
$7,323
AstraZeneca Pharmaceuticals LP
$4,903
SOBI, INC
$975
Regeneron Healthcare Solutions, Inc.
$747
Philips Electronics North America Corporation
$418
Electromed, Inc.
$235
Covis Pharma GmBH
$228
GENZYME CORPORATION
$221
GlaxoSmithKline, LLC.
$194
Covis Pharma B.V.
$175
Novartis Pharmaceuticals Corporation
$164
Baxter Healthcare
$139
Insmed, Inc.
$137
Chiesi USA, Inc.
$105
AbbVie Inc.
$98
SANOFI-AVENTIS U.S. LLC
$81
Covis Pharma GmbH
$69
Genentech USA, Inc.
$66
Alcresta Therapeutics, Inc.
$62
SANOFI PASTEUR INC.
$61
ABBVIE INC.
$55
Boehringer Ingelheim Pharmaceuticals, Inc.
$53
ACADIA Pharmaceuticals Inc
$50
Pharming Healthcare, Inc.
$45
Mylan Specialty L.P.
$36
Advanced Respiratory, Inc
$34
PFIZER INC.
$24
Tactile Systems Technology Inc
$22
Takeda Pharmaceuticals U.S.A., Inc.
$21
Teva Pharmaceuticals USA, Inc.
$18
PARI Respiratory Equipment, Inc.
$16
Philips North America LLC
$15
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 78.6% of total payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ALVESCO · ASMANEX · AirDuo Digihaler · Arikayce · BETHKIS · BEVESPI AEROSPHERE · BEYFORTUS · BRONCHITOL · CREON · DAYBUE · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · ELAPRASE · FASENRA · Flexitouch Plus · Hillrom - Vest System Model 105 Home Care · KITABIS PAK · NUCALA · PAXLOVID · RELIZORB · RUCONEST · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA RESPIMAT · SYMBICORT · SYNAGIS · Synagis · TEZSPIRE · TOBI PODHALER · TOBI Podhaler · The Vest System Model 105 Home Care · The Vest System Model 205 Acute Care · Trilogy 100 · Wellcentive Undiv · XENPOZYME · XOLAIR · Xolair · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (74%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pediatric hematology-oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 6% for pediatric hematology-oncology in TX.

Looking for a pediatric hematology-oncology in Dallas?
Compare pediatric hematology-oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse pediatric hematology-oncologys nearby

Geographic Context

Pediatric Hematology-Oncologys within 10 mi
15
Per 100K population
0.6
County median income
$74,149
Nearest hospital
MEDICAL CITY DALLAS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Copenhaver is a pediatric hematology-oncology, and high industry engagement (speaking/promotional, top 6%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Copenhaver receive payments from pharmaceutical companies?
Yes. Dr. Copenhaver received a total of $16,801 from 33 companies across 282 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Copenhaver) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →